Figure 3.

Inhibition of PI3K∂ by idelalisib reduces NK-cell proliferation and percentage of cytotoxic NK cells. (A) Compiled bar chart showing the proliferative capacity of total CD3⁻CD56⁺ NK cells after 10 days in the presence of IL-2 and different concentrations of Idelalisib or DMSO as vehicle control. (B,C) The shift in the NK-cell composition is depicted as the fold change between days 0 and day 10 of the subsets CD56^brightCD16^neg and CD56^dimCD16^bright. Error bars represent mean ± SEM; ***p ≤ 0.0005; n = 12 HDs.